Responsible Pain Management: Prescribing, Handling and Limiting Opioids: Taped Program

This is a Taped program which you can do at your own pace.

3 Ceu credits are issued upon completion of viewing the program, submitting quiz, and course evaluation.

Program does not have to be viewed in one sitting. you may view parts of the video at your own pace.

You can return to the video at any time.

You have 4 months to complete this program from the date of purchase

This Class Satisfies the MATE ACT Requirement: 

The MATE Act requires increased training for Drug Enforcement Administration (DEA)-registered physicians and practitioners—specifically, a one-time eight-hour training requirement on treating and managing patients with opioid or other substance use disorders. Renewing DEA Registrants will need to satisfy this  requirement as of June 27, 2023 renewals.

Purpose: This program is designed to ensure that oral health clinicians have an awareness of current Federal, New York and New Jersey regulations related to prescribing controlled substances, the science behind these regulations, the history and impact of the current opioid epidemic, and the evolving principles of safe and appropriate pain management.  The program will also address the use of analgesics in palliative care and will highlight management strategies for patients who have substance use disorders and/or present under the influence of psychoactive drugs.

Note: this program includes all of NY’s eight mandated subject areas and fulfills the NY State three-hour requirement for opioid prescriber training.  NJ licensees who attend this program can claim the required one hour of opioid prescriber training and one of the three required hours of internal medicine and pharmacology.  This will also satisfy 3 (THREE) hours of the new, one-time Federal requirement for 8 (EIGHT) hours of training (MATE) to which all prescribers must attest at their next DEA registration renewal beginning on June 27^, 2023.  Previous training that can be documented may also be used to satisfy the requirement.

At the conclusion of this program, participants will be able to:

• Discuss the current opioid epidemic in the US and worldwide and the role of the dentist in reducing the magnitude of this problem
• Describe opioid-reducing strategies for post treatment pain management in dentistry
• Describe how a dentist can prevent or reduce the likelihood of misuse, diversion and abuse of opioids
• Identify State required limits and CDC guidelines related to prescribing controlled substances
• List the responsibilities of the dentist when providing pain management to patients including patient education, proper prescribing and careful documentation

Instructor:     Dr. Hillel Ephros (Hilly) is a graduate of the University of Pennsylvania School of Dental Medicine and St. George’s University School of Medicine. He is a Diplomate of the American Board of Oral and Maxillofacial Surgery and served as an Examiner for that Board from 2003-9. He chairs the Department of Dentistry at St. Joseph’s Regional Medical Center in Paterson, NJ and directs the residency program in oral & maxillofacial surgery sponsored by St. Joseph’s in affiliation with New York Medical College where he is a member of the faculty. Dr. Ephros also has adjunct faculty appointments at Columbia University College of Dental Medicine and Rutgers. He has published in the scientific literature, authored textbook chapters and received awards for teaching including the Archbishop John J. Meyers Outstanding Educator Award in 2003 at Seton Hall University. Dr. Ephros serves as a member of the oral cancer workgroup of the New Jersey task force on the prevention and control of cancer and is the current Chairman of the Oral Cancer Consortium.

This program is for the full dental staff – no prior skills are needed to attend.

The teaching method will be in a lecture format 

DSI Staff or administration do not have any commercial interest or relationship to the speaker.

The content and format of the Continuing Education course is presented without commercial bias and does not claim superiority of any commercial product or service.  No DSI Staff have any financial relationship with the speaker or company.